Enzogrand-D Tablet is a combination pharmaceutical formulation containing Trypsin 48 mg, Bromelain 90 mg, Rutoside 100 mg, and Diclofenac 50 mg, designed to provide effective anti-inflammatory, analgesic, and fibrinolytic effects. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, promoting the resolution of inflammation and edema by enhancing fibrinolysis and reducing swelling in acute and chronic inflammatory conditions. Rutoside, a bioflavonoid, acts as a vascular protector by strengthening capillary walls, reducing capillary permeability, and exhibiting antioxidant properties, thereby aiding in the management of microcirculatory disturbances and preventing oxidative tissue damage. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), provides potent analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes, thereby reducing the synthesis of prostaglandins responsible for pain and inflammation. The synergistic action of these components makes Enzogrand-D effective in the treatment of musculoskeletal disorders, postoperative inflammation, soft tissue injuries, and conditions involving pain and swelling. This combination therapy offers a comprehensive approach by addressing inflammation, pain, and vascular integrity simultaneously. Enzogrand-D should be used under medical supervision, considering contraindications such as hypersensitivity to NSAIDs, bleeding disorders, and gastrointestinal ulcers.